Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $40.33.

DNLI has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Denali Therapeutics in a research note on Wednesday, May 8th. Stifel Nicolaus lowered their target price on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a research note on Wednesday, May 8th. Wedbush lowered their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, May 8th. JPMorgan Chase & Co. raised their price objective on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, UBS Group lowered their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th.

Insider Activity at Denali Therapeutics

In related news, Director Jennifer E. Cook sold 1,458 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the sale, the director now owns 20,038 shares of the company’s stock, valued at $435,425.74. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $22.12, for a total transaction of $663,600.00. Following the sale, the director now owns 34,404 shares of the company’s stock, valued at $761,016.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jennifer E. Cook sold 1,458 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total transaction of $31,682.34. Following the sale, the director now directly owns 20,038 shares in the company, valued at approximately $435,425.74. The disclosure for this sale can be found here. Insiders have sold a total of 32,146 shares of company stock valued at $710,274 over the last 90 days. 7.90% of the stock is owned by corporate insiders.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNLI. Vanguard Group Inc. raised its holdings in Denali Therapeutics by 3.5% during the third quarter. Vanguard Group Inc. now owns 10,597,781 shares of the company’s stock worth $218,632,000 after purchasing an additional 354,798 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Denali Therapeutics by 353.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,981 shares of the company’s stock worth $343,000 after purchasing an additional 12,455 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Denali Therapeutics by 5.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 73,585 shares of the company’s stock worth $1,579,000 after purchasing an additional 3,911 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Denali Therapeutics by 267.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 66,059 shares of the company’s stock worth $1,418,000 after purchasing an additional 48,099 shares in the last quarter. Finally, VELA Investment Management LLC raised its holdings in Denali Therapeutics by 31.4% during the fourth quarter. VELA Investment Management LLC now owns 26,145 shares of the company’s stock worth $561,000 after purchasing an additional 6,246 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Trading Up 1.5 %

Shares of DNLI opened at $23.88 on Friday. The firm has a market capitalization of $3.41 billion, a P/E ratio of -24.88 and a beta of 1.39. The firm has a 50-day moving average price of $21.26 and a 200 day moving average price of $19.36. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $29.22.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.01. During the same quarter in the previous year, the business posted ($0.80) EPS. Equities research analysts predict that Denali Therapeutics will post -2.77 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.